A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma

Trial Profile

A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Aldesleukin (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms PROCLIVITY 01
  • Sponsors Prometheus Laboratories
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 03 Feb 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top